Merus N.V. : Merus to Participate in Upcoming Investor Conferences

ID: 1455435
recent pressrelease next pressrelease

(Thomson Reuters ONE) -


UTRECHT, The Netherlands, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V.
(NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative
bispecific antibody therapeutics, today announced that the Company will
participate in the following upcoming investor conferences:

* Ton Logtenberg, CEO, will present at the 2016 Credit Suisse Antibody Day on
Wednesday, September 7 at 2:40 PM ET at Credit Suisse''s offices at One
Madison Avenue in New York City.
* Management will participate in investor meetings at Citi''s 11(th) Annual
Biotech Conference on Thursday, September 8 at the Mandarin Oriental in
Boston.

A live webcast of the Credit Suisse presentation will be available on the
Investor page of the Company''s website. An archived presentation will be
available for 90 days.

About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full
length human bispecific antibody therapeutics, referred to as Biclonics®.
Biclonics® are based on the full-length IgG format, are manufactured using
industry standard processes and have been observed in preclinical studies to
have several of the same features of conventional monoclonal antibodies, such as
long half-life and low immunogenicity. Merus'' lead bispecific antibody
candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe
as a potential treatment for HER2-expressing solid tumors. Merus'' second
bispecific antibody candidate, MCLA-117, is being developed as a potential
treatment for acute myeloid leukemia. The Company also has a pipeline of
proprietary bispecific antibody candidates in preclinical development, including
MCLA-158, which is designed to bind to cancer stem cells and is being developed
as a potential treatment for colorectal cancer and other solid tumors, and
Biclonics® designed to bind to various combinations of immunomodulatory


molecules, including PD-1 and PD-L1.

Contacts:
Merus N.V.
Shelley Margetson - s.margetson(at)merus.nl
+31 (0)30 253 8800
Argot Partners
Kimberly Minarovich - kimberly(at)argotpartners.com
1-212-600-1902



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Merus N.V. via GlobeNewswire






More information:
http://www.shipfinance.bm/ http://www.archiware.com http://www.diamondhotel.com/news http://www.golarlng.com/ http://www.schaefer-additivsysteme.de http:// http://www.frontline.bm/ http://automaticpetfeeder.net/petmate-pet-cafe-feeder/ http:// http://ww



Keywords (optional):



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: hugin
print pressrelease  send to a friend  

Date: 08/31/2016 - 07:00
Language: English
News-ID 1455435
Character count: 752
Kontakt-Informationen:
Firma: Merus N.V.
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Utrecht
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 145

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 347
Register today: 1
Register yesterday: 6
Members online: 0
Guests online: 50


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.

Categories:


[ more PressReleases ][ RSS-Feed ]